Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
ApexOnco Front Page
Recent articles
The company drops the anti-CD19 x 4-1BB project englumafusp alfa.
Amgen and Gilead deliver lacklustre early clinical results with AMG 355 and denikitug respectively.
First-in-human results prompt a biomarker-defined approach for CID-078.
The company’s conjugate QLS5132 has produced intriguing, but early results.
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
A son of glembatumumab vedotin has just started its phase 1 study.
